Bioventus Inc (NASDAQ: BVS) |
|
Price: $10.4200
$0.15
1.461%
|
Day's High:
| $10.45
| Week Perf:
| -1.14 %
|
Day's Low: |
$ 10.15 |
30 Day Perf: |
17.47 % |
Volume (M): |
160 |
52 Wk High: |
$ 14.38 |
Volume (M$): |
$ 1,662 |
52 Wk Avg: |
$8.37 |
Open: |
$10.34 |
52 Wk Low: |
$3.90 |
|
|
Market Capitalization (Millions $) |
680 |
Shares
Outstanding (Millions) |
65 |
Employees |
500 |
Revenues (TTM) (Millions $) |
556 |
Net Income (TTM) (Millions $) |
-51 |
Cash Flow (TTM) (Millions $) |
16 |
Capital Exp. (TTM) (Millions $) |
1 |
Bioventus Inc
Bioventus Inc. is a global medical technology company that focuses on orthobiologics and orthopedic solutions. The company develops and manufactures innovative products designed to help patients with musculoskeletal conditions and injuries. These products include treatments for osteoarthritis, joint pain, cartilage damage, and bone fractures. Bioventus has a diverse portfolio of products, including surgical and non-surgical options, as well as drugs and devices. The company is committed to improving patient outcomes and quality of life through its advanced orthopedic solutions.
Company Address: 4721 Emperor Boulevard Durham 27703 NC
Company Phone Number: 474-6700 Stock Exchange / Ticker: NASDAQ BVS
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Product Service News
Published Thu, Jan 2 2025 2:40 PM UTC
In a significant shift within the landscape of HealthTech, Bioventus Inc. (Nasdaq: BVS), a renowned player in the sector of active healing innovations, has completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners. This strategic maneuver, finalized on January 2, 2025, represents the culmination of a decision previously announced on October 1, 20...
|
Stock Market Announcement
Published Tue, Oct 1 2024 1:01 PM UTC
Bioventus Inc. Divests Advanced Rehabilitation Business to Fortify Financial Position Amid Strategic RealignmentIn a pivotal move to streamline operations and enhance its financial stability, Bioventus Inc. (Nasdaq: BVS), a prominent force in active healing and rehabilitation technologies, has announced the sale of its Advanced Rehabilitation business, a division of its subs...
|
Bioventus Inc
Bioventus Inc (Nasdaq: BVS), a renowned global leader in active healing innovations, recently reported its financial results for the three months ended March 30, 2024. The company also announced a significant milestone in the form of Amendment No. 5 to its Credit and Guaranty Agreement. These developments highlight Bioventus' commitment to enhancing its financial structure and positioning itself for continued growth in the field of regenerative medicine. Financial Results: During the last five trading days, Bioventus Inc shares experienced a decline, while over the past year, the shares surged by an impressive 315.37%. These fluctuations indicate some short-term market volatility but showcase exceptional long-term growth potential.
|
Bioventus Inc
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, recently announced its fourth quarter and full-year financial results for the year ended December 31, 2023. The company also provided its financial guidance for full-year 2024, indicating a positive outlook for the future. In addition to its financial achievements, Bioventus made headlines with Amendment No. 5 to its Credit and Guaranty Agreement. This amendment, executed on January 18, 2024, demonstrates the company's commitment to optimizing its financial structure and solidifying its position as a frontrunner in regenerative medicine.
|
Financing Agreement
Published Thu, Jan 18 2024 9:15 PM UTC
Bioventus Inc. (Bioventus), a renowned global leader in active healing innovations, recently announced a significant milestone in its financial and operational strategies. The company entered into Amendment No. 5 to its Credit and Guaranty Agreement, paving the way for enhanced flexibility and opportunities for growth. With this amendment, Bioventus aims to solidif...
|
Per Share |
Current |
Earnings (TTM) |
-0.6 $ |
Revenues (TTM) |
8.52 $
|
Cash Flow (TTM) |
0.25 $ |
Cash |
0.66 $
|
Book Value |
2.86 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.6 $
|
Revenues (TTM) |
8.52 $ |
Cash Flow (TTM) |
0.25 $ |
Cash |
0.66 $
|
Book Value |
2.86 $ |
Dividend (TTM) |
0 $ |
|
|
|
U S |
|
88.71 % |
of total Revenue |
U S Pain Treatments |
|
40.64 % |
of total Revenue |
U S Restorative Therapies |
|
18.37 % |
of total Revenue |
U S Surgical Solutions |
|
29.7 % |
of total Revenue |
International |
|
11.59 % |
of total Revenue |
International Pain Treatments |
|
4.92 % |
of total Revenue |
International Restorative Therapies |
|
3.24 % |
of total Revenue |
International Surgical Solutions |
|
3.42 % |
of total Revenue |
|
On March 12 2024 the Bioventus Inc provided following guidance
On March 12, 2024, Bioventus Inc. (Nasdaq: BVS), known for its global leadership in developing innovations for active healing, revealed its financial performance for the fourth quarter and full year of 2023. The company also shared its financial projections for the entirety of 2024.
Based on the figures released by Bioventus, the company has shown positive growth and strong financial performance throughout the year 2023. The financial results for the fourth quarter and full year of 2023, which ended on December 31st, indicate that Bioventus has successfully maintained its position as a global leader in active healing solutions.
Moreover, Bioventus has set ambitious financial targets for the yea...
|
|
|